Solana (NASDAQ:HSDT – Get Free Report) and Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
Earnings & Valuation
This table compares Solana and Nihon Kohden”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Solana | $6.02 million | 17.36 | -$40.89 million | ($109.67) | -0.02 |
| Nihon Kohden | $1.56 billion | 0.97 | $95.79 million | $0.59 | 15.34 |
Profitability
This table compares Solana and Nihon Kohden’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Solana | -1,427.15% | -67.57% | -24.09% |
| Nihon Kohden | 6.08% | 9.46% | 6.68% |
Analyst Ratings
This is a breakdown of current ratings for Solana and Nihon Kohden, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Solana | 1 | 1 | 1 | 1 | 2.50 |
| Nihon Kohden | 0 | 1 | 0 | 1 | 3.00 |
Solana currently has a consensus price target of $3.50, suggesting a potential upside of 95.53%. Given Solana’s higher probable upside, analysts plainly believe Solana is more favorable than Nihon Kohden.
Volatility and Risk
Solana has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Nihon Kohden has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
Institutional and Insider Ownership
18.6% of Solana shares are held by institutional investors. Comparatively, 0.1% of Nihon Kohden shares are held by institutional investors. 14.4% of Solana shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Nihon Kohden beats Solana on 8 of the 14 factors compared between the two stocks.
About Solana
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
About Nihon Kohden
Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.
Receive News & Ratings for Solana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solana and related companies with MarketBeat.com's FREE daily email newsletter.
